Post
of 26,236
Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch
https://thestreetreports.com/stocks-under-0-1...ess-watch/
A group of sub-$0.10 and low-priced small-cap stocks is drawing increased attention as investors rotate into high-beta, low-float names across biotechnology, artificial intelligence, and critical minerals. With volatility rising and capital flowing into speculative growth themes, several companies are emerging on trader and investor watchlists.
Biotech Momentum: Iterum Therapeutics (NASDAQ: ITRM) & Polaryx Therapeutics (NASDAQ: PLYX)
Biotech names ITRM have seen increased activity, moving sharply in pre-market trading as investors target rare-disease and orphan-drug opportunities. The company’s focus on late-infantile neuronal ceroid lipofuscinosis (LINCL) and related pediatric neurodegenerative disorders positions it within a niche where limited treatment options and orphan-drug economics can drive outsized valuation shifts on clinical progress.
Critical Minerals & Supply Chain Theme: American Lithium Minerals (OTC: AMLM)
AMLM continues to gain traction as a diversified critical minerals explorer with exposure to lithium, gold, silver, copper, and rare earth elements. The company’s Nevada lithium asset has recently been validated through independent analysis, while its broader portfolio spans Quebec polymetallic projects, Chile copper and silver assets, and international gold exposure.
With increasing focus on U.S. supply-chain security, EV batteries, AI infrastructure, and electrification metals, AMLM’s multi-commodity approach helps reduce risk while maintaining upside exposure. Rising trading activity and a low public float structure have also placed the stock on momentum watchlists.
AI Meets Drug Discovery: BullFrog AI Holdings (NASDAQ: BFRG)
BullFrog AI is gaining visibility after announcing a commercial agreement with a top 5 global pharmaceutical company to apply its bfLEAP® AI platform to identify and prioritize drug targets in major depressive disorder (MDD). The deal includes exclusive access to a target candidate, highlighting the growing role of AI and machine learning in accelerating drug discovery.
Balance Sheet Reset: Quince Therapeutics (NASDAQ: QNCX)
Quince Therapeutics recently announced the settlement of its European Investment Bank loan for $5.5 million, removing a key financial overhang. Balance sheet improvements are often closely watched in small-cap biotech, particularly as companies reposition for clinical advancement and strategic flexibility.
Earnings Catalyst Ahead: ADM Endeavors (OTCQB: ADMQ)
ADM Endeavors remains on watch ahead of its March 2026 earnings report, following its expansion into a 100,000-square-foot $13M production facility designed to significantly increase output capacity. Growth in manufacturing apparel and custom promotional products continues to support the company’s expansion strategy.
The Bigger Picture
Across sectors, a common theme is emerging:
low-priced, low-float stocks with defined catalysts are regaining attention.
Biotech → rare disease and AI-driven drug discovery
Critical minerals → EVs, energy transition, supply chains
Small-cap growth → earnings expansion and balance sheet resets
Most early-stage moves begin quietly—before broader participation follows.
As volatility and sector rotation continue, these stocks under $0.10 represent a cross-section of where speculative capital is beginning to flow.
https://thestreetreports.com/stocks-under-0-1...ess-watch/
A group of sub-$0.10 and low-priced small-cap stocks is drawing increased attention as investors rotate into high-beta, low-float names across biotechnology, artificial intelligence, and critical minerals. With volatility rising and capital flowing into speculative growth themes, several companies are emerging on trader and investor watchlists.
Biotech Momentum: Iterum Therapeutics (NASDAQ: ITRM) & Polaryx Therapeutics (NASDAQ: PLYX)
Biotech names ITRM have seen increased activity, moving sharply in pre-market trading as investors target rare-disease and orphan-drug opportunities. The company’s focus on late-infantile neuronal ceroid lipofuscinosis (LINCL) and related pediatric neurodegenerative disorders positions it within a niche where limited treatment options and orphan-drug economics can drive outsized valuation shifts on clinical progress.
Critical Minerals & Supply Chain Theme: American Lithium Minerals (OTC: AMLM)
AMLM continues to gain traction as a diversified critical minerals explorer with exposure to lithium, gold, silver, copper, and rare earth elements. The company’s Nevada lithium asset has recently been validated through independent analysis, while its broader portfolio spans Quebec polymetallic projects, Chile copper and silver assets, and international gold exposure.
With increasing focus on U.S. supply-chain security, EV batteries, AI infrastructure, and electrification metals, AMLM’s multi-commodity approach helps reduce risk while maintaining upside exposure. Rising trading activity and a low public float structure have also placed the stock on momentum watchlists.
AI Meets Drug Discovery: BullFrog AI Holdings (NASDAQ: BFRG)
BullFrog AI is gaining visibility after announcing a commercial agreement with a top 5 global pharmaceutical company to apply its bfLEAP® AI platform to identify and prioritize drug targets in major depressive disorder (MDD). The deal includes exclusive access to a target candidate, highlighting the growing role of AI and machine learning in accelerating drug discovery.
Balance Sheet Reset: Quince Therapeutics (NASDAQ: QNCX)
Quince Therapeutics recently announced the settlement of its European Investment Bank loan for $5.5 million, removing a key financial overhang. Balance sheet improvements are often closely watched in small-cap biotech, particularly as companies reposition for clinical advancement and strategic flexibility.
Earnings Catalyst Ahead: ADM Endeavors (OTCQB: ADMQ)
ADM Endeavors remains on watch ahead of its March 2026 earnings report, following its expansion into a 100,000-square-foot $13M production facility designed to significantly increase output capacity. Growth in manufacturing apparel and custom promotional products continues to support the company’s expansion strategy.
The Bigger Picture
Across sectors, a common theme is emerging:
low-priced, low-float stocks with defined catalysts are regaining attention.
Biotech → rare disease and AI-driven drug discovery
Critical minerals → EVs, energy transition, supply chains
Small-cap growth → earnings expansion and balance sheet resets
Most early-stage moves begin quietly—before broader participation follows.
As volatility and sector rotation continue, these stocks under $0.10 represent a cross-section of where speculative capital is beginning to flow.